NCT05969275View on ClinicalTrials.gov

Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock

PHASE2RecruitingINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions
Septic ShockSepsisPathologic ProcessesShockSystemic Inflammatory Response SyndromeInflammationInfections
Interventions
BIOLOGICAL

Allogeneic umbilical cord-derived human mesenchymal stromal cells

Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells

OTHER

Placebo

Intravenous infusion of placebo, with excipients

Trial Locations (2)

K1H 8L6

RECRUITING

The Ottawa Hospital (General Campus), Ottawa

K1Y 4E9

RECRUITING

The Ottawa Hospital (Civic Campus), Ottawa

Sponsors
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Stem Cell Network

OTHER

collaborator

Canadian Critical Care Trials Group

OTHER

collaborator

Technische Universität Dresden

OTHER

lead

Ottawa Hospital Research Institute

OTHER